Literature DB >> 22442427

Neurobehavioral dysfunction in ALS has a negative effect on outcome and use of PEG and NIV.

A Chiò1, A Ilardi, S Cammarosano, C Moglia, A Montuschi, A Calvo.   

Abstract

OBJECTIVE: To assess the effect of neurobehavioral dysfunction on amyotrophic lateral sclerosis (ALS) survival and on the use of life-prolonging therapies in a population-based setting.
METHODS: Of the 132 patients diagnosed with ALS in the province of Torino, Italy, between January 1, 2007, and June 30, 2008, 128 participated in the study. Neurobehavioral dysfunction was assessed with the Frontal Systems Behavior Scale (FrSBe), using the Family Rating forms, administered within 4 months from diagnosis.
RESULTS: The 128 patients included 71 men and 57 women, with a mean age at onset of 64.7 (SD 11) years. Forty-one patients (32.0%) had a neurobehavioral dysfunction and 9 (7.0%) an isolated dysexecutive behavior. Enteral nutrition (EN) and noninvasive ventilation (NIV) were performed with similar frequencies in patients with and without neurobehavioral dysfunction. Patients with neurobehavioral dysfunction had a significantly shorter survival than those with a normal FrSBe score (median survival, 3.3 vs 4.3 years; p = 0.02). Patients with isolated dysexecutive behavior had a shorter survival than those without neurobehavioral dysfunction (median survival, 2.5 vs 4.5 years; p = 0.03). Patients with neurobehavioral dysfunction had a shorter survival after EN and NIV, while patients with isolated dysexecutive behavior had a shorter survival after NIV but not after EN. The negative effect of comorbid neurobehavioral dysfunction and of isolated dysexecutive behavior on survival persisted under the Cox multivariate model.
CONCLUSIONS: The presence of neurobehavioral dysfunction or of isolate dysexecutive behavior in ALS at diagnosis is a strong predictor of a poor outcome, partially related to a reduced efficacy of life-prolonging therapies.

Entities:  

Mesh:

Year:  2012        PMID: 22442427     DOI: 10.1212/WNL.0b013e31824e8f53

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  20 in total

Review 1.  [Amyotrophic lateral sclerosis. Multisystem degeneration].

Authors:  A Hübers; A C Ludolph; A Rosenbohm; E H Pinkhardt; J H Weishaupt; J Dorst
Journal:  Nervenarzt       Date:  2016-02       Impact factor: 1.214

2.  Comorbidity of dementia with amyotrophic lateral sclerosis (ALS): insights from a large multicenter Italian cohort.

Authors:  Francesca Trojsi; Mattia Siciliano; Cinzia Femiano; Gabriella Santangelo; Christian Lunetta; Andrea Calvo; Cristina Moglia; Kalliopi Marinou; Nicola Ticozzi; Gianluca Drago Ferrante; Carlo Scialò; Gianni Sorarù; Amelia Conte; Yuri M Falzone; Rosanna Tortelli; Massimo Russo; Valeria Ada Sansone; Adriano Chiò; Gabriele Mora; Barbara Poletti; Paolo Volanti; Claudia Caponnetto; Giorgia Querin; Mario Sabatelli; Nilo Riva; Giancarlo Logroscino; Sonia Messina; Antonio Fasano; Maria Rosaria Monsurrò; Gioacchino Tedeschi; Jessica Mandrioli
Journal:  J Neurol       Date:  2017-09-15       Impact factor: 4.849

3.  Cognitive impairment across ALS clinical stages in a population-based cohort.

Authors:  Adriano Chiò; Cristina Moglia; Antonio Canosa; Umberto Manera; Rosario Vasta; Maura Brunetti; Marco Barberis; Lucia Corrado; Sandra D'Alfonso; Enrica Bersano; Maria Francesca Sarnelli; Valentina Solara; Jean Pierre Zucchetti; Laura Peotta; Barbara Iazzolino; Letizia Mazzini; Gabriele Mora; Andrea Calvo
Journal:  Neurology       Date:  2019-08-13       Impact factor: 9.910

4.  ALS Cognitive Behavioral Screen (ALS-CBS): normative values for the Italian population and clinical usability.

Authors:  Lucio Tremolizzo; Andrea Lizio; Gabriella Santangelo; Susanna Diamanti; Christian Lunetta; Francesca Gerardi; Sonia Messina; Stefania La Foresta; Nilo Riva; Yuri Falzone; Massimo Filippi; Susan C Woolley; Valeria Ada Sansone; Mattia Siciliano; Carlo Ferrarese; Ildebrando Appollonio
Journal:  Neurol Sci       Date:  2019-12-05       Impact factor: 3.307

5.  The capacity to consent to treatment in amyotrophic lateral sclerosis: a preliminary report.

Authors:  Rossella Spataro; Vincenzo La Bella
Journal:  J Neurol       Date:  2020-08-06       Impact factor: 4.849

6.  Primitive reflexes in amyotrophic lateral sclerosis: prevalence and correlates.

Authors:  Lucio Tremolizzo; Emanuela Susani; Christian Lunetta; Massimo Corbo; Carlo Ferrarese; Ildebrando Appollonio
Journal:  J Neurol       Date:  2014-04-13       Impact factor: 4.849

7.  Clinical features and differential diagnosis of flail arm syndrome.

Authors:  Annemarie Hübers; Viviane Hildebrandt; Susanne Petri; Katja Kollewe; Andreas Hermann; Alexander Storch; Frank Hanisch; Stephan Zierz; Angela Rosenbohm; Albert C Ludolph; Johannes Dorst
Journal:  J Neurol       Date:  2015-12-24       Impact factor: 4.849

Review 8.  Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease.

Authors:  Federica Agosta; Daniele Altomare; Cristina Festari; Stefania Orini; Federica Gandolfo; Marina Boccardi; Javier Arbizu; Femke Bouwman; Alexander Drzezga; Peter Nestor; Flavio Nobili; Zuzana Walker; Marco Pagani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-01       Impact factor: 9.236

9.  Patterns of spontaneous brain activity in amyotrophic lateral sclerosis: a resting-state FMRI study.

Authors:  Chunyan Luo; Qin Chen; Rui Huang; Xueping Chen; Ke Chen; Xiaoqi Huang; HeHan Tang; Qiyong Gong; Hui-Fang Shang
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

10.  ALS and Frontotemporal Dysfunction: A Review.

Authors:  Eugene Y Achi; Stacy A Rudnicki
Journal:  Neurol Res Int       Date:  2012-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.